Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incretin Action in Physiology and Diabetes
NCT02550548Phase 1Completed
- Start
- Apr 2016
- Primary completion
- Apr 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of glucose-dependent insulinotropic polypeptide[1-42] and Glucagon-like peptide 1 in type 2 diabetes mellitus (T2DM) (4 arms). Primary endpoint: Beta cell sensitivity. Started Apr 2016; status: completed.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]Glucagon-like peptide 1
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02550548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550548.